TNF and rheumatoid arthritis: Targeted depletion of B cells with a monoclonal antibody (mAb) such as rituximab (anti-CD20) appears to be efficient and cost-effective in patients with RA that is refractory to disease-modifying anti-rheumatic drugs (DMARDS) and anti-tumor necrosis factor-alpha therapy (anti-TNF) [1–3].